Eris Lifesciences Ltd

Eris Lifesciences Limited announced on July 30, 2026, the allotment of 4,816 equity shares at a premium of Rs 450.04 per share, pursuant to the exercise of options under the ESOP-2017 Scheme, increasing the company's paid-up share capital from Rs 13,85,78,489 to Rs 13,85,83,305.

Revenue from operations grew 12.97% YoY to Rs 873.25 crore during the quarter. Profit before tax (PBT) jumped 11.42% YoY to Rs 179.49 crore in Q1 FY27. EBITDA rose 7.1% YoY to Rs 296 crore from Rs 277 crore in the year-ago quarter. However, EBITDA margin contracted to 33.9% in Q1 FY27 from 35.8% in Q1 FY26. During the quarter, revenue from domestic branded formulations (DBF) segment stood at Rs 801 crore, up 14% YoY Meanwhile, revenue from the international business increased 5% YoY to Rs 72 crore during the quarter. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products.Powered by Capital Market - Live

Net profit of ERIS Lifesciences rose 20.68% to Rs 142.39 crore in the quarter ended June 2026 as against Rs 117.99 crore during the previous quarter ended June 2025. Sales rose 12.63% to Rs 869.03 crore in the quarter ended June 2026 as against Rs 771.56 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales869.03771.56 13 OPM %34.0435.86 - PBDT251.56231.61 9 PBT179.49161.10 11 NP142.39117.99 21 Powered by Capital Market - Live

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 29 July 2026.

Net profit of ERIS Lifesciences rose 200.10% to Rs 281.61 crore in the quarter ended March 2026 as against Rs 93.84 crore during the previous quarter ended March 2025. Sales rose 7.07% to Rs 752.29 crore in the quarter ended March 2026 as against Rs 702.60 crore during the previous quarter ended March 2025. For the full year,net profit rose 76.08% to Rs 619.52 crore in the year ended March 2026 as against Rs 351.84 crore during the previous year ended March 2025. Sales rose 8.18% to Rs 3114.89 crore in the year ended March 2026 as against Rs 2879.26 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales752.29702.60 7 3114.892879.26 8 OPM %36.2135.92 -35.9635.33 - PBDT228.98206.12 11 935.28804.33 16 PBT159.41128.87 24 655.78488.87 34 NP281.6193.84 200 619.52351.84 76 Powered by Capital Market - Live

ERIS Lifesciences announced that the Board of Directors of the Company at its meeting held on 20 May 2026, inter alia, have recommended the interim dividend of Rs 7.21 per equity Share (i.e. 721%) , subject to the approval of the shareholders.

Total revenue from operations rose 7.26% to Rs 756.56 crore in Q4 FY26 over Q4 FY25. Profit before tax (PBT) stood at Rs 159.41 crore in Q4 FY26, up 23.69% from Rs 128.87 crore recorded in the same quarter last year. During the quarter EBITDA stood at Rs 274 crore, up 8% compared with Rs 252 crore posted in same quarter last year. EBITDA margin expanded to 36.2% in Q4 FY26 as against 35.8% in Q4 FY25. Revenue from domestic branded formulation (DBF) business jumped 12% YoY to Rs 671 crore in Q4 FY26. The International Business fell 8% to Rs 86 crore in Q4 FY26. The company declared an interim dividend of Rs 7.21 per fully paid-up equity share of Re 1 each (721%) for FY27. It has fixed Friday, May 29, 2026, as the record date to determine shareholders' eligibility for the interim dividend. The dividend will be paid on or before June 19, 2026. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products. Powered by Capital Market - Live

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 20 May 2026.

ERIS Lifesciences has allotted 24,396 equity shares under ESOP on 11 May 2026. The paid-up share capital of the Company accordingly stands increased from Rs 13,85,42,887/- (13,85,42,887 equity shares of Re 1/- each) to Rs 13,85,67,256/- (13,85,67,256 equity shares of Re 1/- each).

Eris Lifesciences has received affirmation in credit ratings for non convertible debentures and bank facilities at IND AA; Stable/ IND A1+ from India Ratings and Research. The company's issuer rating has been affirmed at IND AA; Stable.